BIONTECH

1st Quarter 2022 Financial Results & Corporate Update

May 9, 2022



This Slide Presentation Includes Forward-looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: our expected revenues and net profit related to sales of our COVID-19 vaccine, referred to as COMIRNATY® where approved for use under full or conditional marketing authorization, in territories controlled by our collaboration partners, particularly for those figures that are derived from preliminary estimates provided by our partners; our pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors after our initial sales to national governments; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; competition from other COVID-19 vaccines or related to our other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the rate and degree of market acceptance of our COVID-19 vaccine and, if approved, our investigational medicines; the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; the timing of and our ability to obtain and maintain regulatory approval for our product candidates; our collaboration with Pfizer to develop and market a COVID-19 vaccine (including a potential booster dose of BNT162b2 and/or a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence); the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; our ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of our third-party collaborators to continue research and development activities relating to our development candidates and investigational medicines; the impact of the COVID-19 pandemic on our development programs, supply chain, collaborators and financial performance; unforeseen safety issues and claims for personal injury or death arising from the use of our COVID-19 vaccine and other products and product candidates developed or manufactured by us; our ability to progress our Malaria, Tuberculosis and HIV programs, including timing for selecting clinical candidates for these programs and the commencement of a clinical trial, as well as any data readouts; the nature and duration of support from the World Health Organization, the European Commission and other organizations with establishing infrastructure; the development of sustainable vaccine production and supply solutions on the African continent and the nature and feasibility of these solutions; our estimates of research and development revenues, commercial revenues, cost of sales, research and development expenses, sales and marketing expenses, general and administrative expenses, capital expenditures, income taxes, shares outstanding; our ability and that of our collaborators to commercialize and market our product candidates, if approved, including our COVID-19 vaccine; our ability to manage our development and expansion; regulatory developments in the United States and foreign countries; our ability to effectively scale our production capabilities and manufacture our products, including our target COVID-19 vaccine production levels, and our product candidates; and other factors not known to us at this time. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. You should review the risks and uncertainties described under the heading "Risk Factors" in this presentation for the three months ended March 31, 2022 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at https://www.sec.gov/. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech's current expectations and speak only as of the date hereof.



Safety Information

COMIRNATY® (the Pfizer-BioNTech COVID-19 vaccine) has been granted conditional marketing authorization (CMA) by the European Commission to prevent coronavirus disease 2019 (COVID-19) in people from 5 years of age. The vaccine is administered as a primary course of 2 doses, 3 weeks apart. In addition, the CMA has been expanded to include a booster dose (third dose) at least 6 months after the second dose in individuals 12 years of age and older. For immunocompromised individuals, a third primary course dose may be given at least 28 days after the second dose. The European Medicines Agency's (EMA's) human medicines committee (CHMP) has completed its rigorous evaluation of COMIRNATY®, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine are now available.

IMPORTANT SAFETY INFORMATION:

- Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.
- There is an increased risk of myocarditis and pericarditis following vaccination with Comirnaty. These conditions can develop within just a few days after vaccination, and have primarily occurred within 14 days. They
 have been observed more often after the second vaccination, and more often in younger males. Available data suggest that the course of myocarditis following vaccination is not different from
 myocarditis or pericarditis in general.
- Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions (e.g. dizziness, palpitations, increases in heart rate, alterations in blood pressure, paraesthesia, hypoaesthesia and sweating) may occur in association with the vaccination process itself. Stress-related reactions are temporary and resolve on their own. Individuals should be advised to bring symptoms to the attention of the vaccination provider for evaluation. It is important that precautions are in place to avoid injury from fainting.
- Vaccination should be postponed in individuals suffering from acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.
- As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
- The efficacy and safety of the vaccine has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of Comirnaty may be lower in immunocompromised individuals. As with any vaccine, vaccination with COMIRNATY® may not protect all vaccine recipients. Individuals may not be fully protected until 7 days after their second dose of vaccine.
- In clinical studies, adverse reactions in participants 16 years of age and older were injection site pain (> 80%), fatigue (> 60%), headache (> 50%), myalgia and chills (> 30%), arthralgia (> 20%), pyrexia and injection site swelling (> 10%) and were usually mild or moderate in intensity and resolved within a few days after vaccination. A slightly lower frequency of reactogenicity events was associated with greater age.
- The overall safety profile of COMIRNATY® in participants 5 to 15 years of age was similar to that seen in participants 16 years of age and older.
- The most frequent adverse reactions in children 5 to 11 years of age were injection site pain (>80%), fatigue (>50%), headache (>30%), injection site redness and swelling (>20%), myalgia and chills (>10%).
- The most frequent adverse reactions in clinical trial participants 12 to 15 years of age were injection site pain (> 90%), fatigue and headache (> 70%), myalgia and chills (> 40%), arthralgia and pyrexia (> 20%).
- A large amount of observational data from pregnant women vaccinated with Comirnaty during the second and third trimester have not shown an increase in adverse pregnancy outcomes. While data on pregnancy outcomes following vaccination during the first trimester are presently limited, no increased risk for miscarriage has been seen. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition or post-natal development. Comirnaty can be used during pregnancy.
- No effects on the breast fed newborn/infant are anticipated since the systemic exposure of breast feeding woman to Comirnaty is negligible. Observational data from women who were breast feeding after vaccination have not shown a risk for adverse effects in breast fed newborns/infants. Comirnaty can be used during breast feeding. Interactions with other medicinal products or concomitant administration of COMIRNATY® with other vaccines has not been studied.
- For complete information on the safety of COMIRNATY® always make reference to the approved Summary of Product Characteristics and Package Leaflet available in all the languages of the European Union on the EMA website.

The black equilateral triangle V denotes that additional monitoring is required to capture any adverse reactions. This will allow quick identification of new safety information. Individuals can help by reporting any side effects they may get. Side effects can be reported to EudraVigilance or directly to BioNTech using email medinfo@biontech.de, telephone +49 6131 9084 0, or via the website www.biontech.de



Safety Information

AUTHORIZED USE IN THE U.S.

COMIRNATY[®] (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. It is also authorized under EUA to provide a 2-dose primary series to individuals 5 years of age and older, a third primary series dose to individuals 5 years of age and older who have been determined to have certain kinds of immunocompromise, a single booster dose to individuals 12 years of age and older who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY[®], a single booster dose to individuals 18 years of age and older who have completed primary vaccination with a different authorized COVID-19 vaccine, a second booster dose to individuals 50 years of age and older who have received a first booster dose of any authorized COVID-19 vaccine. The booster dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise and who have received a first booster dose of any authorized COVID-19 vaccine. The booster schedule is based on the labeling information of the vaccine used for the primary series.

IMPORTANT SAFETY INFORMATION

Individuals should not get the vaccine if they:

- had a severe allergic reaction after a previous dose of this vaccine
- had a severe allergic reaction to any ingredient of this vaccine

Individuals should tell the vaccination provider about all of their medical conditions, including if they:

- have any allergies
- · have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)
- have a fever
- have a bleeding disorder or are on a blood thinner
- are immunocompromised or are on a medicine that affects the immune system
- are pregnant, plan to become pregnant, or are breastfeeding
- have received another COVID-19 vaccine
- have ever fainted in association with an injection

The vaccine may not protect everyone. Side effects reported with the vaccine include:

- There is a remote chance that the vaccine could cause a severe allergic reaction
 - A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of the vaccine. For this reason, vaccination providers may ask individuals to stay at the place where they received the vaccine for monitoring after vaccination
 - o Signs of a severe allergic reaction can include difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness
 - o If an individual experiences a severe allergic reaction, they should call 9-1-1 or go to the nearest hospital
- Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine, more commonly in males under 40 years of age than among females and older males. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:
 - o chest pain
 - $\circ \quad \text{shortness of breath} \quad$
 - \circ $\,$ feelings of having a fast-beating, fluttering, or pounding heart $\,$
- Additional side effects that have been reported with the vaccine include:
 - severe allergic reactions; non-severe allergic reactions such as injection site pain; tiredness; headache; muscle pain; chills; joint pain; fever; injection site swelling; injection site redness; nausea; feeling unwell; swollen lymph nodes (lymphadenopathy); decreased appetite; diarrhea; vomiting; arm pain; and fainting in association with injection of the vaccine
- These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The possible side effects of the vaccine are still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away

Data on administration of this vaccine at the same time as other vaccines have not yet been submitted to FDA. Individuals considering receiving this vaccine with other vaccines should discuss their options with their healthcare provider. Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit https://www.vaers.hhs.gov or call 1-800- 822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.





O1 First Quarter 2022 Highlights Ugur Sahin, CEO

02 Pipeline Update Özlem Türeci, CMO


03

Financial Results Jens Holstein, CFO






Our Vision: Harnessing The Power Of The Immune System To Fight Human Diseases





Highlights in Q1 2022



- Reported Q1 total revenues of €6.4 bn¹
- Signed pandemic preparedness contract with Federal Republic of Germany through 2027
- Multiple new deals signed:
 - Matinas lipid nanocrystal collaboration
 - Regeneron collaboration to advance BNT116 in combination with Libtayo in NSCLC

- Invoiced ~750 m doses globally in Q1
- FDA authorized 4th dose in adults 50 years+ and in immunocompromised individuals 12 years+
- Continued label expansion in multiple regions for booster dose in 12+ years

- BNT211 (CLDN6 CAR-T cell therapy) Phase 1/2 data presented at AACR showed manageable safety profile and signs of clinical activity
- First RiboMab BNT141 (CLDN18.2 antibody) entered Phase 1 clinical study in solid tumors

1 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021 as well as the Quarterly Report as of and for the three months ended March 31, 2022, filed as an exhibit to BioNTech's Current Report on Form 6-K. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively.



NSCLC = non-small cell lung cancer

Proactive Approach to Managing COVID-19 at a Global Scale

Strong global position to tackle COVID-19 pandemic



- Delivered nearly 3.4 bn¹ doses cumulatively to >175 countries and regions
- On track to achieve pledge to deliver a total of 2 bn doses to lowand middle-income countries by end of 2022

Innovation to stay ahead of COVID-19

- Optimized formulation
- V Pediatric label expansion
 - Submission for boosters in children 5 to <12 yrs
 - Evaluating 3-dose primary regimen in children
 6 months to <5 yrs; data expected in coming weeks
- Future pandemic preparedness
 - Monitoring of emerging variants
 - Rapid data-guided vaccine adaptation
- Pre-emptive approach to variants
 - Comprehensive variant-adapted and next-gen vaccine development program
 - Broad research program to study anti-SARS-CoV-2 immune profile after vaccinations, boosters, breakthrough infections to inform strategy





Once in a generation opportunity to transform medicine





O1 First Quarter 2022 Highlights Ugur Sahin, CEO

02 Pipeline Update Özlem Türeci, CMO

03

Financial Results Jens Holstein, CFO



Corporate Outlook Ryan Richardson, Chief Strategy Officer



COVID-19 Vaccine R&D Strategy to Drive Pandemic Preparedness

	Purpose	Latest Developments		
Landscape Research	Inform Understanding of Dynamic SARS-CoV-2 Immunity	Example Server Joint Server For BIOLOGY DioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive. New Results Pollow this prep Omicron breakthrough infection drives cross-variant neutralization and memory B cell formation Jasmin Quandt, A dexander Mulik, Nadine Salisch, Bonny Gaby Lui, Sebastian Lutz, Kimberly Krüger, Ann-Kathrin Wallisch, Perza Adams-Quack, Maren Bacher, Andrew Finlayson, Orkun Ozhelvaci, Isabel Vogler, Katharina Grikscheit, Sebastian Hoehl, Udo Goetsch, Sandra Ciesek, Ozlem Türeci, Ugur Sahin rei: terrore/Idoi ore/10 1101/2022 04 01 486695	 Omicron Infection After Vaccination Drives Cross-Variant Neutralization and B Cell Immunity¹ Exposure to Omicron spike boosts strong and broad neutralizing activity against SARS-CoV-2 VOCs Robust recall and expansion of preformed memory B cells that recognize epitopes shared across variants Data suggest Omicron-adapted vaccination after COMIRNATY could provide similar cross-strain immunity 	
Product Research	Explore Various Follow- On and Next-Gen Vaccine Approaches	COMIRNATY Omicron- N Adapted	Nono-/ Multi- T Cell Pan-Coronavirus valent Enhancing covering	
Product Development	Assess Safety, Tolerability and Immunogenicity of Variant-Adapted Vaccines		ical trials evaluating mono- or bivalent variant adapted eviewed and discussed with regulators	

11 bioRxiv. Omicron breakthrough infection drives cross-variant neutralization and memory B cell formation; April 1, 2022. Available at: <u>https://www.biorxiv.org/content/10.1101/2022.04.01.486695v1.full.pdf</u> VOC, variants of concern




Comprehensive Clinical Response Strategy to Omicron Variant

Assessing Safety, Tolerability and Immunogenicity of an Omicron-Adapted Vaccine

Evaluating different Omicron-adapted monovalent vaccine regimens

- N~1500, 18-55 years
- Vaccine experienced and naïve subjects



Evaluating bivalent Wild-Type/Omicron-adapted and Omicron-adapted vaccines

- N~650, >55 years
- Two dosages: 30 µg and 60 µg



¹² BioNTech. Available at: <u>https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-initiate-study-evaluate-omicron-based-covid</u>. Accessed January 2022; ClinicalTrials.gov. Available at: <u>https://www.clinicaltrials.gov/ct2/show/NCT04955626</u>. Accessed March 2022.


Oncology: Advancement Across Multiple Modalities and Indications

Drug class	Platform	Product candidate	Indication (targets)	Pre-clinical	Phase 1	Phase 2	Phase 3
	FixVac	BNT111	Advanced melanoma				
(fixed of sh	(fixed combination	BNT112	Prostate cancer				
	of shared cancer	BNT113	HPV16+ head and neck cancer				
	antigens)	BNT115 ¹	Ovarian cancer ¹				
		BNT116	NSCLC				
	iNeST		1L melanoma				
	(patient specific	Autogene cevumeran	Adjuvant colorectal cancer				
mRNA	cancer antigen immune therapy)	(BNT122) ²	Solid tumors				
	Intratumoral Immunotherapy	SAR441000 (BNT131) ³	Solid tumors (IL-12sc, IL15-sushi, GM-CSF, IFNα)				
	RiboMabs	BNT141	Multiple solid tumors (CLDN18.2)				
	(mRNA-encoded antibodies)	BNT142	Multiple solid tumors (CD3+CLDN6)				
	RiboCytokines	BNT151	Multiple solid tumors (optimized IL-2)				
	(mRNA-encoded cytokines)	BNT152, BNT153	Multiple solid tumors (IL-7, IL-2)				
	CAR-T Cells +	BNT211	Multiple solid tumors (CLDN6)				
	Carvac	BNT212	Pancreatic, other cancers (CLDN18.2)				
Cell Therapies	Neoantigen-based T cells	BNT221 (NEO-PTC-01)	Multiple solid tumors				
	TCR engineered T cells	To be selected	All tumors				
	ntibodies Next-Gen CP Immunomodulators GEN1046 (BNT311) ⁴ GEN1042 (BNT312) ⁴ Targeted Cancer Antibodies BNT321 (MVT-5873)	CEN1046 (BNIT211)4	Metastatic NSCLC (PD-L1x4-1BB)				
Antibodies Imm		Multiple solid tumors (PD-L1x4-1BB)					
		GEN1042 (BNT312) ⁴	Multiple solid tumors (CD40x4-1BB)				
		BNT321 (MVT-5873)	Pancreatic cancer (sLea)				
SMIM	Toll-Like Receptor Binding	BNT411	Solid tumors (TLR7)				

13 ¹BNT115 is currently being studied in an investigator-initiated Phase 1 trial. ²Collaboration with Genentech ³Collaboration with Sanofi. ⁴Collaboration with Genmab. SMIM, Small Molecule Immunomodulators



Focused Execution in 2022 Across 5 Phase 2 Programs in Various Solid Tumor Types



14 R/R, refractory/relapsed; HPV16+, human papilloma virus type 16 positive; HNSCC, head and neck squamous cell carcinoma; NK cell, Natural killer cell, CPI, checkpoint inhibitor 1 Collaboration with Genentech, 2 Collaboration with Genmab.

BIONTECH

BNT211: CAR-T Cell Program with Potential Targeting Multiple High-Need Solid Tumors

2nd generation CAR

- Directed against CLDN6
- Cancer specific carcino-embryonic antigen
- Expressed in multiple solid cancers with high medical need


CARVac


 drives in vivo expansion, persistence and efficacy of CAR-T cells

CLDN6 not present in healthy tissues

CLDN6 expressed in multiple cancers

BNT211 CAR Structure





5 CLDN6, Claudin-6; CAR-T cells, chimeric antigen receptor engineered T cells; scFv, single chain variable fragment; RP2D, recommended Phase 2 dose; NOS, not otherwise specified; Reinhard K, et al. Science 2020; 367:446-453



15

BNT211: CAR-T in Solid Tumors Encouraging Efficacy and Safety Profiles Presented at AACR



CLDN6 CAR-T cells as monotherapy or combined with CARVac well tolerated at dose levels evaluated to date $(1x10^7 \text{ and } 1x10^8 \text{ CAR-T})$

- Grade 1-2 CRS seen in 70% of patients at 1x10⁸ CAR-T dose, manageable by administration of tocilizumab
- 2 DLTs observed, both patients fully recovered and showed clinical benefit
- MTD not reached yet

Robust CAR-T engraftment achieved in all patients translating into clinical activity: **ORR 43%, DCR of 86%** in evaluable patients (n=14; $1x10^7$ and $1x10^8$ CAR-T)

Efficacy


- 6 PR, 5 SD+, 1 SD (Testicular, ovarian and other tumors, 6 weeks post-infusion)
- 5 testicular cancer patients show promising responses at 1x10⁸ CAR-T: ORR 80%, DCR 100%; 1 CR, 3 PR, 1 SD
- CARVac supports CAR-T engraftment and mediates
 physiologic expansion plus upregulation of survival pathways
- Some patients show continuing CAR-T persistence (>150 days post infusion)
- Patients with initial PR showed further deepening of responses

DL1: 1x107 CAR-T; DL2: 1x108 CAR-T

CLDN6, Claudin-6; DLT, dose-limiting toxicity; MTD, maximum tolerated dose; CRS, cytokine release syndrome; CR, complete response; DCR, disease control rate; DL, dose level; ORR, overall response rate; PR, partial response; SD, stable disease



Robust CAR-T Engraftment Seen in all Patients and Persisting CAR-T in Responding Patients




Data cut-off: MAR 10, 2022.

DL1: 1x107 CAR-T; DL2: 1x108 CAR-T

CRS, cytokine release syndrome; DCR, disease control rate; DL, dose level; DLT, dose-limiting toxicity; ORR, overall response rate; PR, partial response; SD, stable disease; *At first tumor assessmen (6 weeks post infusion); **2 patients died due to disease progression before first tumor assessment.



Efficacy Observed at 6 Weeks Post Infusion




DL, dose level; CR, complete response; DCR, disease control rate; EoT, end of trial (due to PD); ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease, SD+, SD with shrinkage of target lesions; *50% lymphodepletion

Continuing Responses in Testicular Cancer with One PR Deepening to CR




Durability of responses



Weeks



Responses in Two Testicular Cancer Patients with Relapse After Prior Treatment





Agenda

O1 First Quarter 2022 Highlights Ugur Sahin, CEO

02

Pipeline Update Özlem Türeci, CMO



Financial Results Jens Holstein, CFO



Corporate Outlook Ryan Richardson, Chief Strategy Officer




Key Highlights For Q1 2022



1 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021 as well as the Quarterly Report as of and for the three months ended March 31, 2022, filed as an exhibit to BioNTech's Current Report on Form 6-K. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively.



First Quarter 2022 COVID-19 Vaccine Commercial Revenues



Strong Q1 2022 - BioNTech reiterates 2022 financial year guidance

1 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021
 as well as the Quarterly Report as of and for the three months ended March 31, 2022, filed as an exhibit to BioNTech's Current Report on Form 6-K. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively.



Q1 2022 Financial Results – Profit or Loss

(in millions, except per share data) ¹	Q1 2022	Q1 2021
Research & development revenues	€12.4	€20.9
Commercial revenues ²	6,362.2	2,027.5
Total revenues	€6,374.6	€2,048.4
Cost of sales	(1,294.1)	(233.1)
Research and development expenses	(285.8)	(216.2)
Sales and marketing expenses	(14.3)	(8.7)
General and administrative expenses	(90.8)	(38.9)
Other operating income less expenses	63.1	110.7
Operating income	€4,752.7	€1,662.2
Finance income less expenses	265.4	(19.9)
Income taxes	(1,319.3)	(514.2)
Profit for the period	€3,698.8	€1,128.1

Earnings per share		
Basic profit for the period per share	€15.13	€4.64
Diluted profit for the period per share	€14.24	€4.39

1 Numbers have been rounded, numbers presented may not add up precisely to the totals and may have been adjusted in the table context. Presentation of the consolidated statements of profit or loss has been condensed.

2 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021 as 24 well as the Quarterly Report as of and for the three months ended March 31, 2022, filed as an exhibit to BioNTech's Current Report on Form 6-K. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively.



2022 Financial Year Guidance Reiterated

COVID-19 Vaccine Revenues for FY 2022 ¹	
Estimated BioNTech COVID-19 vaccine revenues	€ 13 – 17 bn
Planned FY 2022 Expenses and Capex ¹	
R&D expenses	€ 1,400 - 1,500 m
SG&A expenses	€ 450 - 550 m
Capital expenditure	€ 450 - 550 m
Estimated FY 2022 Tax Assumptions	
BioNTech Group estimated annual effective income tax rate	~ 28 % ²

1 Ranges reflect current base case projections and do not include potential effects caused by or driven from additional collaborations or potential M&A transactions.
 2 BioNTech Group estimated annual effective income tax rate decreased from 31.6% (FY 2021) to ~28% (FY 2022) mainly due to decreasing average trade tax rates.



Agenda

O1 First Quarter 2022 Highlights Ugur Sahin, CEO

02

Pipeline Update Özlem Türeci, CMO


03

Financial Results Jens Holstein, CFO





Significant Pipeline Expansion and Maturation Expected in 2022



Invest in Foundation to Enable Accelerated Innovation and Expansion

Digital & Al Capabilities | Technologies | Development Team | Manufacturing | Global Footprint



COVID-19 Vaccine Outlook 2022





Pipeline of variant-adapted and next generation COVID-19 vaccines in multiple active clinical trials

Upcoming Data

BNT162b2	Timing
 Data for 4th dose in adults, aged 16 to 65 years² 	ongoing
 Data for 3-dose regimen in children, aged 6 months to <5 years 	coming weeks

Follow-on and next generation vaccines	
 Omicron-adapted vaccine: monovalent, bivalent - 3rd and/or 4th dose 	coming weeks
 Multiple updates: Follow on and next-gen vaccines 	2H



Further Expected Pipeline Milestones in 2022

4 Infectious Disease First-In-Human Trial Starts			
 Shingles vaccine¹ 	2H		
Tuberculosis vaccine ²	2H		
HSV 2 vaccine	2H		
Malaria vaccine	2H		

3 Oncology First-in-Human Trial Starts			
 BNT141 – RiboMab, solid tumors 	FPD in January		
 BNT142 – RiboMab, solid tumors 	1H		
 BNT116 – FixVac in combination w/Libtayo, NSCLC 	2H		
3 Data Updates			
 BNT161 – Influenza mRNA vaccine¹ 	2022		
 BNT122³ Phase 2 – iNeST in combination w/Pembrolizumab, 1L Melanoma 	2H		
 BNT211 Phase 1/2 – CAR-T/CLDN6+, multiple solid tumors 	2H		
HSV 2, Herpes simplex virus type 2; FPD, first patient dosed; CLDN, Claudin; NSCLC, non-small cell lung cancer	BIONTEC		

HSV 2, Herpes simplex virus type 2; FPD, first patient dosed; CLDN, Claudin; NSCLC, non-small cell lung cancer 29 1 Partnered with Pfizer, 2 Collaboration with BMGF, 3 Partnered with Genentech

SAVE THE DATE

BIONTECH

Annual General Meeting June 1, 2022

Virtual Capital Markets Day June 29, 2022





